Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Published Online: 2020-06-?
Journal: The Lancet Haematology•Publisher: Elsevier BV
Authors: Alexsandra Croockewit•Anders Waage•Andrew Spencer•Angelo Belotti•Angelo Palmas•Anna Maria Cafro•Anna Maria Morelli•Anna Marina Liberati•Anna Pascarella•Annemiek Broijl•Barbara Gamberi•Bronno van der Holt•Caroline Mandigers•Christoph Driessen•Elena Zamagni•Francesca Gay•Francesca Patriarca•Gerard Bos•Giorgina Specchia•Giulia Benevolo•Giuseppe A Palumbo•Heinz Ludwig•Iolanda D Vincelli•Ka Lung Wu•Luca Dozza•Lucia Pantani•Ludek Pour•Marc Durian•Maria Teresa Petrucci•Mariella Grasso•Marinus van Marwijk Kooy•Mario Boccadoro•Mark-David Levin•Markus Hansson•Massimo Offidani•Meletios A Dimopoulos•Meral Beksac•Michele Cavo•Monica Galli•Monique Minnema•Niels Frost Andersen•Paula Ypma•Peter A von dem Borne•Peter Gimsing•Pieter Sonneveld•Renato Zambello•Rinske Boersma•Roman Hajek•Rossella Troia•Sara Aquino•Sonja Zweegman•Stefania Oliva•Stelvio Ballanti•Susanna Carvalho•Thilo Zander•Tommaso Caravita di Toritto•Ulf-Henrik Mellqvist•Vincent H J van der Velden•Vittorio Montefusco•Vladimir Maisnar
